In the letter, Astellas said its reasoning was to “uphold the integrity of the 340B program and address the risk of duplicate discounts and diversion.” Safety-net hospitals without an in-house pharmacy will be allowed to order Xtandi at the discounted price through one contract pharmacy.
The drugmaker will be the 24th pharmaceutical company to curb products discounted through the federal 340B program, nonprofit organization 340B Health said July 3.
The nonprofit said the decision is “depriving hospitals of crucial resources,” and it is watching two federal appeals court cases on the matter of contract pharmacies in the 340B program.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.